Telomir Pharmaceuticals (NASDAQ:TELO) Raised to Strong-Buy at Maxim Group

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) was upgraded by research analysts at Maxim Group to a “strong-buy” rating in a research note issued to investors on Thursday, Zacks reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Get Telomir Pharmaceuticals alerts:

Get Our Latest Report on Telomir Pharmaceuticals

Telomir Pharmaceuticals Stock Performance

NASDAQ:TELO opened at $1.23 on Thursday. Telomir Pharmaceuticals has a one year low of $0.89 and a one year high of $2.09. The firm has a market cap of $84.60 million, a price-to-earnings ratio of -1.35 and a beta of -0.25. The firm’s fifty day moving average is $1.15 and its two-hundred day moving average is $1.25.

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.72).

Hedge Funds Weigh In On Telomir Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. OneDigital Investment Advisors LLC acquired a new position in Telomir Pharmaceuticals in the 2nd quarter worth about $29,000. World Investment Advisors acquired a new stake in Telomir Pharmaceuticals in the fourth quarter valued at approximately $47,000. Bank of New York Mellon Corp acquired a new stake in Telomir Pharmaceuticals in the second quarter valued at approximately $66,000. Finally, BlackRock Inc. purchased a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $359,000.

Telomir Pharmaceuticals Company Profile

(Get Free Report)

Telomir Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases and conditions associated with aging. The company’s research is centered on telomere biology, an area involving the protective structures at the ends of chromosomes that generally shorten as cells divide and age.

Telomir’s lead product candidate is TELOMIR-1, an orally administered small-molecule compound being investigated for its potential to address telomere shortening and support healthier cellular aging.

Further Reading

• Five stocks we like better than Telomir Pharmaceuticals
• J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
• 2 Stocks Breaking Out Post-FOMC With One Thing in Common
• Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
• These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons

Receive News & Ratings for Telomir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telomir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.